Meeting
2013 ASCO Annual Meeting
Vascular endothelial growth factor expression in hepatitis C virus (HCV)-related advanced hepatocellular carcinoma (HCC) compared with hepatitis Β virus (HBV)-related advanced HCC.
Authors
Yu Yun Shao
Graduate Institute of Oncology, National Taiwan University, Taipei City, Taiwan
Yu Yun Shao , Min-Shu Hsieh , Chung-Yi Huang , Yung-Ling Chang , Chih-Hung Hsu , Ann-Lii Cheng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 4115)
DOI
10.1200/jco.2013.31.15_suppl.4115
Abstract #
4115
Poster Bd #
26B
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Autologous cytotoxic T-cell receptor T cell therapy (SCG101) against hepatitis B surface antigen phase I/II trial for patients with advanced hepatitis B-related hepatocellular carcinoma.
First Author: Ghassan K. Abou-Alfa
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208.
First Author: Ann-Lii Cheng
Poster
2020 Gastrointestinal Cancers Symposium
Impact of baseline hepatitis B viremia and management on outcomes in patients (Pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Outcomes from REACH-2.
First Author: Peter R. Galle
Poster
2018 Gastrointestinal Cancers Symposium
Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S).
First Author: Daniel E. Meyers